SARS-CoV-2 antibody response after mRNA vaccination in healthcare workers with and without previous COVID-19, a follow-up study from the University Hospital in Krakow, Poland

Frontiers in Immunology

Immunology

Barbara Żółtowska¹  Wojciech Sydor²  Barbara Maziarz³  Elżbieta Sochacka-Tatara⁴  Agnieszka Pac⁴  Piotr Heczko⁵  Jadwiga Wójkowska-Mach⁵  Wiktor Szczuciński⁵  Estera Jachowicz⁵  Karolina Gutkowska⁵  Izabella Owsianka⁶ 

[1] Center for Innovative Therapy, Clinical Research Coordination Center, University Hospital in Krakow, Krakow, Poland;Center for Innovative Therapy, Clinical Research Coordination Center, University Hospital in Krakow, Krakow, Poland;Department of Rheumatology and Immunology, Jagiellonian University Medical College, Krakow, Poland;Department of Diagnostics, Department of Clinical Biochemistry, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland;Department of Epidemiology and Preventive Medicine, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland;Department of Microbiology, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland;Doctoral School of Medical and Health Sciences, Jagiellonian University Medical College, Krakow, Poland;Department of Microbiology, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland;

关键词: COVID-19;    antibody levels;    healthcare workers;    COVID-19 immune response;    mRNA vaccine against SARS-CoV-2;   

DOI  :  10.3389/fimmu.2022.1071204

 received in 2022-11-03, accepted in 2022-12-13,  发布年份 2023

来源: Frontiers

【 摘 要 】

IntroductionHealthcare workers (HCWs) from the beginning of the pandemic have been at risk of exposure to SARS-CoV-2, so they were vaccinated as first.ObjectivesThe purpose of the study was to determine the level of antibodies against SARS-CoV-2 in HCWs before and after vaccination with mRNA preparations according to previous COVID- 19.Patients and methodsThe HCWs from the University Hospital in Krakow completed two surveys: the baseline survey before receiving the first dose of vaccine (in January 2021) and the follow-up survey in June 2021. In parallel, two blood samples were collected from each participant at baseline and at follow-up. Total anti-SARS-CoV-2 antibody levels were measured using the ECLIA technique.ResultsAt baseline, 41.1% of HCWs had positive antibody test results, and at follow-up, the vaccinated HCWs had almost 100 times higher antibody levels than the unvaccinated HCWs. Participants under 30 years of age had significantly higher antibody levels in June than older HCWs. Among participants with positive antibody test results in January, HCWs who had experienced asymptomatic COVID-19 had more than five times higher antibody levels in June than HCWs self-reported severe COVID-19. In total, 86.9% of HCWs received Comirnaty or Spikevax. The incidence rate of COVID-19 in the unvaccinated vs. vaccinated group was 13 times higher, 20.5% and 1.9% respectively.ConclusionsThese results confirm the effectiveness of vaccination in the prevention of COVID-19 in HCWs. It is worth getting vaccinated regardless of previous infection. Furthermore, vaccination among HCWs under 30 years of age induced more effective antibody production compared to older individuals.

【 授权许可】

Unknown   
Copyright © 2023 Owsianka, Pac, Jachowicz, Gutkowska, Szczuciński, Maziarz, Sochacka-Tatara, Heczko, Sydor, Żółtowska and Wójkowska-Mach